Cargando…

Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laurence, Jeffrey, Mulvey, J. Justin, Seshadri, Madhav, Racanelli, Alexandra, Harp, Joanna, Schenck, Edward J., Zappetti, Dana, Horn, Evelyn M., Magro, Cynthia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410014/ https://www.ncbi.nlm.nih.gov/pubmed/32771488 http://dx.doi.org/10.1016/j.clim.2020.108555

Ejemplares similares

Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage
por: Laurence, Jeffrey, et al.
Publicado: (2022)

The skin as a critical window in unveiling the pathophysiologic principles of COVID-19
por: Magro, Cynthia, et al.
Publicado: (2021)

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
por: Magro, Cynthia, et al.
Publicado: (2020)

The effects of Eculizumab on the pathology of malignant atrophic papulosis
por: Magro, Cynthia M, et al.
Publicado: (2013)

Analysis of complement deposition and viral RNA in placentas of COVID-19 patients
por: Mulvey, J. Justin, et al.
Publicado: (2020)

Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019
por: Magro, Cynthia M., et al.
Publicado: (2020)

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
por: Chonat, Satheesh, et al.
Publicado: (2020)

Complement activation and effect of eculizumab in scleroderma renal crisis
por: Devresse, Arnaud, et al.
Publicado: (2016)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023)

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Eculizumab and Complement Activation in Anti−glomerular Basement Membrane Disease
por: Nithagon, Pravarut, et al.
Publicado: (2021)

The differing pathophysiologies that underlie COVID‐19‐associated perniosis and thrombotic retiform purpura: a case series
por: Magro, C.M., et al.
Publicado: (2021)

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021)

Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
por: Vitkauskaitė, Monika, et al.
Publicado: (2022)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010)

Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
por: Busutti, Marco, et al.
Publicado: (2020)

Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation
por: Yerly, Patrick, et al.
Publicado: (2022)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
por: Torres, Everardo Arias, et al.
Publicado: (2021)

Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series
por: Burwick, Richard M., et al.
Publicado: (2022)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab
por: Ellithi, Moataz, et al.
Publicado: (2021)

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy
por: Sridharan, Meera, et al.
Publicado: (2022)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Eculizumab Dosing in Infants
por: Kobrzynski, M., et al.
Publicado: (2018)

The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea
por: Kim, Hyerim, et al.
Publicado: (2017)

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19
por: Leone, Valentina Fanny, et al.
Publicado: (2022)

Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report
por: Nakamura, Masahiko, et al.
Publicado: (2022)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Severe COVID-19: A multifaceted viral vasculopathy syndrome
por: Magro, Cynthia M., et al.
Publicado: (2021)

The Extended Use of Eculizumab in Pregnancy and Complement Activation–Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys—The Future Is Now?
por: Stefanovic, Vedran
Publicado: (2019)

Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab
por: Asif, Arif, et al.
Publicado: (2016)

Eculizumab in Early-Stage Pregnancy
por: Morales, Enrique, et al.
Publicado: (2020)

WITHDRAWN: A mechanistic analysis placental intravascular thrombus formation in COVID-19 patients
por: Mulvey, J. Justin, et al.
Publicado: (2020)

Evaluation of Albumin Kinetics in Critically Ill Patients With Coronavirus Disease 2019 Compared to Those With Sepsis-Induced Acute Respiratory Distress Syndrome
por: Su, Chang, et al.
Publicado: (2021)

Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report
por: Calvaruso, Luca, et al.
Publicado: (2019)

Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report
por: Abe, Tomohiro, et al.
Publicado: (2017)

Novel complement factor H gene mutation causing atypical haemolytic uraemic syndrome: early Eculizumab prevents acute dialysis
por: Collett, James, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rkq4jlug37ksdkvan36b6vtbjm